1. Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements. <br/ > <br/ >2. Male or female patients between 18 and 60 years of age (both inclusive). <br/ > <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) Note: If rapid antigen test has been performed and patient found positive then RT-PCR will be performed prior to randomization. <br/ > <br/ >4. Patients with mild COVID-19 and have following symptoms and signs prior to randomization. <br/ >Mild: Upper respiratory tract symptoms (&/or fever) without shortness of breath or hypoxia. <br/ > <br/ >5. Patients who are able to consume oral medications. <br/ > <br/ >6. Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Refrain from donating sperm, and either abstain from sexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, or must agree to use contraception. <br/ > <br/ >7. Females who are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (WOCBP), or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier method), or be abstinent from sexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention, a WOCBP must have a negative highly sensitive pregnancy test (urine or serum test is required) within 24 hours before the first dose of study intervention. <br/ >

1. Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements. <br/ > <br/ >2. Male or female patients between 18 and 60 years of age (both inclusive). <br/ > <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) Note: If rapid antigen test has been performed and patient found positive then RT-PCR will be performed prior to randomization. <br/ > <br/ >4. Patients with mild COVID-19 and have following symptoms and signs prior to randomization. <br/ >Mild: Upper respiratory tract symptoms (&/or fever) without shortness of breath or hypoxia. <br/ > <br/ >5. Patients who are able to consume oral medications. <br/ > <br/ >6. Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Refrain from donating sperm, and either abstain from sexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, or must agree to use contraception. <br/ > <br/ >7. Females who are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (WOCBP), or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier method), or be abstinent from sexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention, a WOCBP must have a negative highly sensitive pregnancy test (urine or serum test is required) within 24 hours before the first dose of study intervention. <br/ >

1. Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements. <br/ > <br/ >2. Male or female patients between 18 and 60 years of age (both inclusive). <br/ > <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) Note: If rapid antigen test has been performed and patient found positive then RT-PCR will be performed prior to randomization. <br/ > <br/ >4. Patients with mild COVID-19 and have following symptoms and signs prior to randomization. <br/ >Mild: Upper respiratory tract symptoms (&/or fever) without shortness of breath or hypoxia. <br/ > <br/ >5. Patients who are able to consume oral medications. <br/ > <br/ >6. Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Refrain from donating sperm, and either abstain from sexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, or must agree to use contraception. <br/ > <br/ >7. Females who are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (WOCBP), or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier method), or be abstinent from sexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention, a WOCBP must have a negative highly sensitive pregnancy test (urine or serum test is required) within 24 hours before the first dose of study intervention. <br/ >

1. Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements. <br/ > <br/ >2. Male or female patients between 18 and 60 years of age (both inclusive). <br/ > <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) Note: If rapid antigen test has been performed and patient found positive then RT-PCR will be performed prior to randomization. <br/ > <br/ >4. Patients with mild COVID-19 and have following symptoms and signs prior to randomization. <br/ >Mild: Upper respiratory tract symptoms (&/or fever) without shortness of breath or hypoxia. <br/ > <br/ >5. Patients who are able to consume oral medications. <br/ > <br/ >6. Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Refrain from donating sperm, and either abstain from sexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, or must agree to use contraception. <br/ > <br/ >7. Females who are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (WOCBP), or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier method), or be abstinent from sexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention, a WOCBP must have a negative highly sensitive pregnancy test (urine or serum test is required) within 24 hours before the first dose of study intervention. <br/ >